Aralez Pharma Stock Analysis (NASDAQ:ARLZ)

Add to My Stocks
$1.61 $0.02 (1.23%) ARLZ stock closing price Apr 28, 2017 (Closing)
Watch Robo Advisor Video of ARLZ Stock Analysis
Aralez Pharma
Updated on : Apr 28, 2017
previous close
ARLZ 1.6 (0%)
S&P 500 2384.2 (0%)
Closing Price On: Apr 27, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Drugs
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q3
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
-1.3%
Operating Profit
Operating Margin:
-219.9%
Sector Average:
-1.1%
5 Quarter Net Profit
Net Margins
2016-Q3
%
LTM Margin
Debt/Equity Ratio
Debt:
74.5M
Debt/Equity Ratio:
 0.5
Compared to the industry
Cash Flow
Operating cash flow:
-$10.9M
Net Income:
-$20.6M
PROS      CONS
Recent Growth
PS Valuation
Long Term Growth
Operating Margins
Net Margins
High Debt Burden
PE Valuation
ROIC
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
ARLZ PS :
2
Industry PS :
4.9
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-93.3%
Return on Equity:
-77.7%
Free Cash Flow Margin:
-90.2%
Double Tap To Exit Full Screen
0:00
/

Aralez Pharma Analysis Video

166 5 2

View Aralez Pharma stock analysis video. This is our ARLZ analyst opinion covering the buy and sell arguments for ARLZ stock.

Aralez Pharmaceuticals Inc Stock Rating (1.9/5)

Our Aralez Pharma stock opinion is based on fundamentals of the company. This Aralez Pharma stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy ARLZ stock?

  • The Year Over Year (YoY) revenue growth for Aralez Pharma was 134.2% in 2016 Q3.
  • The lower PS ratio 2 for ARLZ stock versus Medical-Drugs industry average of 4.9 is a positive for the company.

Should you sell ARLZ stock?

  • Revenue declined at a CAGR of -1.3% over the last 5 years.
  • Over the last twelve months, Aralez Pharma posted an average operating loss margin of -219.9%.
  • Aralez Pharma registered an average TTM Net loss of -211.7%.
  • With a debt/equity ratio of  0.5, Aralez Pharma is highly leveraged in comparison to Medical peers.
  • PE ratio is meaningless for ARLZ stock as the company has losses.
  • The company has a negative Return on Invested Capital of -93.3%, which is a red flag.
  • Aralez Pharma has a negative ROE (Return On Equity) of -77.7%, indicating the company is not profitable.
  • The company has a negative free cash flow margin of -90.2%.

Comments on this video and Aralez Pharma stock

You may be interested in our Astrazeneca valuation video